Another potential target for immunotherapy is B7-H3, a member of the same B7 ligand family as PD-L1, which has been found to be highly expressed in SCLC, with B7-H3 expressed in 64.9% of SCLC cases compared to PD-L1 in 7.3% of cases[57]. Here, CD276 is linked to small cell lung carcinoma.